PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 2, 20260 citations

Comparison of concurrent chemoradiotherapy followed by immunotherapy and induction chemoimmunotherapy followed by radiotherapy in unresectable stage III NSCLC: a retrospective cohort study.

View Full Paper
QXQinhao XuYQYana QiXZXiangyu Zhai

Key Points

  • To compare the effectiveness and safety of concurrent chemoradiotherapy followed by immunotherapy versus induction chemoimmunotherapy followed by radiotherapy in unresectable stage III NSCLC.
  • Conducted a retrospective cohort study
  • Analyzed patient outcomes post-treatment
  • Compared cCRT+IO and ICT+RT
  • cCRT+IO showed superior efficacy compared to ICT+RT
  • Safety profile of cCRT+IO was manageable
  • Significant improvement in treatment outcomes with cCRT+IO

Abstract

Compared with ICT+RT, cCRT+IO demonstrated superior efficacy with a manageable safety profile in unresectable stage III NSCLC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xu et al. (2026) studied this question.

synapsesocial.com/papers/69a52e04f1e85e5c73bf1442https://doi.org/10.1080/14796694.2026.2637732
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-22024 · 75 citations
  2. 2Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R2024 · 56 citations
  3. 3Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity2023 · 160 citations
  4. 4The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist).2025 · 11 citations
  5. 5AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).2020 · 14 citations